Toggle Main Menu Toggle Search

Open Access padlockePrints

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Lookup NU author(s): Dr Tobias Menne

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2024 American Society of HematologyPosttransplant lymphoproliferative disorder (PTLD) is a rare complication of solid organ transplantation, and cytotoxic chemotherapy is associated with treatment-related morbidity and mortality. Current treatment takes a sequential, risk-stratified approach, and patients with low-risk disease after initial immunotherapy can avoid escalation to immunochemotherapy. TIDaL is a prospective, single-arm phase 2 trial investigating the activity and tolerability of ibrutinib combined with risk-stratified therapy for first-line treatment of PTLD. Eligible patients were adults with newly diagnosed CD20+ B-cell PTLD after solid organ transplant and performance status 0 to 2. Initial treatment comprised 49 days of ibrutinib 560 mg once daily, with 4 doses of weekly rituximab. Treatment response on interim scan and baseline International Prognostic Index were used to allocate patients to either a low-risk arm (who continued ibrutinib, alongside 4 further doses of 3-weekly rituximab) or high-risk (escalation to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] immunochemotherapy, with ibrutinib continuing in patients aged <65 years). The primary outcome was complete response on interim scan, achieved by 11 of 38 patients (29%; 95% confidence interval [CI], 15-46). This did not reach the prespecified threshold for clinically significant activity. Secondary outcomes included allocation to the low-risk arm (41% of patients), 2-year progression-free survival (58%; 95% CI, 44-76), and 2-year overall survival (76%; 95% CI, 63-91). Adverse events were mostly hematological, gastrointestinal, and infective. Although TIDaL does not support adding ibrutinib into first-line treatment of PTLD, increasing the proportion of patients who can be treated without cytotoxic chemotherapy remains an important aim of future research. This trial was registered at www.clinicaltrials.gov as # ISRCTN32667607.


Publication metadata

Author(s): Chaganti S, Maycock S, McIlroy G, Jackson A, Bishop R, Johnson S, Kanfer E, Kassam S, Cwynarski K, Wrench D, Arumainathan A, Fox CP, Johnson R, McKay P, Paneesha S, Rowntree C, Balotis C, Collins GP, Davies A, Wright J, Burns S, Laurence A, Wheatley K, Menne T

Publication type: Article

Publication status: Published

Journal: Blood

Year: 2024

Pages: epub ahead of print

Online publication date: 21/04/2024

Acceptance date: 02/04/2018

ISSN (print): 0006-4971

ISSN (electronic): 1528-0020

Publisher: Elsevier B.V.

URL: https://doi.org/10.1182/blood.2024023847

DOI: 10.1182/blood.2024023847

PubMed id: 38643491


Altmetrics

Altmetrics provided by Altmetric


Share